Anca Prica
Researcher Next ID · RN-042785
Researcher · Medicine
Toronto, New Zealand
- Works count
- 357
- Citation count
- 2,368
- H-index
- 23
- i10-index
- 49
Research interests
Publications
Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2405888
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study
The Lancet Oncology · 2024 · 10.1016/s1470-2045(24)00508-4
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines
European Heart Journal - Cardiovascular Pharmacotherapy · 2023 · 10.1093/ehjcvp/pvad031
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines
European Heart Journal - Cardiovascular Pharmacotherapy · 2023 · 10.1093/ehjcvp/pvad031
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.18.02096
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial
The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30912-9
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial
The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30912-9
Current projects
No projects listed.